Impact of helicobacter pylori eradication on circulating adiponectin in humans

Helicobacter

Volumn 18, Issue 2, 2013, Pages 158-164

  Ando, Takashi ^a   Ishikawa, Takeshi ^b,c   Takagi, Tomohisa ^b   Imamoto, Eiko ^a   Kishimoto, Etsuko ^b   Okajima, Akira ^a   Uchiyama, Kazuhiko ^b   Handa, Osamu ^b   Yagi, Nobuaki ^b   Kokura, Satoshi ^b,c   Naito, Yuji ^b   Mizuno, Shigeto ^d   Asakawa, Akihiro ^e   Inui, Akio ^e   Yoshikawa, Toshikazu ^c  

^a Social Insurance Kyoto Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Helicobacter pylori; Metabolic syndrome

Indexed keywords

ADIPONECTIN; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DISEASE MARKER; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEROLOGY; TREATMENT DURATION;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; PROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875020440     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12028     Document Type: Article

References (44)

1. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ 1999;319:1157-62.
2. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Hawkey C, Atherton J. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation 2000;101:1647-52.
3. Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, Marz W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. Am J Cardiol 2004;93:219-20.
4. Takashima T, Adachi K, Kawamura A, Yuki M, Fujishiro H, Rumi MA, Ishihara S, Watanabe M, Kinoshita Y. Cardiovascular risk factors in subjects with Helicobacter pylori infection. Helicobacter 2002;7:86-90.
5. Ohnishi M, Fukui M, Ishikawa T, Ohnishi N, Ishigami N, Yoshioka K, Hasegawa G, Yoshikawa T, Nakamura N. Helicobacter pylori infection and arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2008;57:1760-4.
6. Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA, Ahmed EA, Abdel Rahman MS. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis 2008;17:86-94.
7. Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc 2004;96:1470-6.
8. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998;316:1130-2.
9. Rothenbacher D, Hoffmeister A, Bode G, Miller M, Koenig W, Brenner H. Helicobacter pylori heat shock protein 60 and risk of coronary heart disease: a case control study with focus on markers of systemic inflammation and lipids. Atherosclerosis 2001;156:193-9.
10. Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008;103:3005-10.
11. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996;41:458-61.
12. Quadri R, Rossi C, Catalfamo E, Masoero G, Lombardo L, Della Monica P, Rovera L, Pera A, Cavello Perin P. Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2000;10:263-6.
13. Fernandini-Paredes GG, Mezones-Holguin E, Vargas-Gonzales R, Pozo-Briceno E, Rodriguez-Morales AJ. In patients with type 2 diabetes mellitus, are glycosylated hemoglobin levels higher for those with Helicobacter pylori infection than those without infection? Clin Infect Dis 2008;47:144-6.
14. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010;103:190-6.
15. Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007;121:229-38.
16. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-81.
17. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54-9.
18. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
19. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
20. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
21. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
22. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767-70.
23. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
24. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231-4.
25. Thjodleifsson B, Olafsson I, Gislason D, Gislason T, Jogi R, Janson C. Infections and obesity: a multinational epidemiological study. Scand J Infect Dis 2008;40:381-6.
26. Torisu T, Takata Y, Ansai T, et al. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. J Atheroscler Thromb 2009;16:691-7.
27. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori. Gut 1995;37:199-204.
28. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
29. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002;103:137-42.
30. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003;278:40352-63.
31. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-62.
32. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-62.
33. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
34. Consolazio A, Borgia MC, Ferro D, Iacopini F, Paoluzi OA, Crispino P, Nardi F, Rivera M, Paoluzi P. Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. Aliment Pharmacol Ther 2004;20:289-94.
35. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-23.
36. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
37. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Mace K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416-26.
38. Wang ZV, Schraw TD, Kim JY, Khan T, Rajala MW, Follenzi A, Scherer PE. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol 2007;27:3716-31.
39. Pellicano R, Oliaro E, Fagoonee S, et al. Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. Int Angiol 2009;28:469-73.
40. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003;52:637-40.
41. Tatsuguchi A, Miyake K, Gudis K, et al. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004;99:2121-7.
42. Ukkola O, Poykko S, Paivansalo M, Kesaniemi YA. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med 2008;40:465-73.
43. Yano Y, Toshinai K, Inokuchi T, Kangawa K, Shimada K, Kario K, Nakazato M. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009;204:590-4.
44. Fujiwara Y, Higuchi K, Arafa UA, Uchida T, Tominaga K, Watanabe T, Arakawa T. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 2002;49:1298-302.